In parallel, ImmuneOnco has recently submitted an IND application to the NMPA for a subcutaneous formulation of IMM0306, which has been accepted for review. This next-generation delivery method aims to enhance patient convenience and long-term treatment adherence. Combined with prior clinical trial progress or IND submissions across multiple immune-mediated indications—including relapsed/refractory follicular lymphoma (in combination with lenalidomide; Phase III approved), SLE (Phase Ib/II), neuromyelitis optica spectrum disorder (NMOSD; Phase Ib/III), lupus nephritis (LN; Phase II), and primary membranous nephropathy (PMN; IND accepted)—the systematic advancement of IMM0306 in autoimmune diseases underscores the broad therapeutic potential of the CD47×CD20 dual-target mechanism and establishes a solid platform for future expansion into additional autoimmune conditions.